Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 2
2007 3
2008 1
2009 3
2010 7
2011 7
2012 3
2013 4
2014 7
2015 12
2016 10
2017 8
2018 13
2019 13
2020 13
2021 13
2022 9
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
[Minimal residual disease in AML].
Taga T. Taga T. Rinsho Ketsueki. 2020;61(4):343-349. doi: 10.11406/rinketsu.61.343. Rinsho Ketsueki. 2020. PMID: 32378579 Review. Japanese.
Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Nishimura A, Yokoyama K, Naruto T, Yamagishi C, Imamura T, Nakazono H, Kimura S, Ito M, Sagisaka M, Tanaka Y, Piao J, Namikawa Y, Yanagimachi M, Isoda T, Kanai A, Matsui H, Isobe T, Sato-Otsubo A, Higuchi N, Takada A, Okuno H, Saito S, Karakawa S, Kobayashi S, Hasegawa D, Fujisaki H, Hasegawa D, Koike K, Koike T, Rai S, Umeda K, Sano H, Sekinaka Y, Ogawa A, Kinoshita A, Shiba N, Miki M, Kimura F, Nakayama H, Nakazawa Y, Taga T, Taki T, Adachi S, Manabe A, Koh K, Ishida Y, Takita J, Ishikawa F, Goto H, Morio T, Mizutani S, Tojo A, Takagi M. Nishimura A, et al. Among authors: taga t. Sci Adv. 2023 Dec 15;9(50):eadj4407. doi: 10.1126/sciadv.adj4407. Epub 2023 Dec 13. Sci Adv. 2023. PMID: 38091391 Free PMC article.
TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
Hara Y, Shiba N, Yoshida K, Yamato G, Kaburagi T, Shiraishi Y, Ohki K, Shiozawa Y, Kawamura M, Kawasaki H, Sotomatsu M, Takizawa T, Matsuo H, Shimada A, Kiyokawa N, Tomizawa D, Taga T, Ito E, Horibe K, Miyano S, Adachi S, Taki T, Ogawa S, Hayashi Y. Hara Y, et al. Among authors: taga t. Genes Chromosomes Cancer. 2023 Jul;62(7):412-422. doi: 10.1002/gcc.23147. Epub 2023 Apr 27. Genes Chromosomes Cancer. 2023. PMID: 37102302
Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
Sakaguchi H, Umeda K, Kato I, Sakaguchi K, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito A, Noma H, Horibe K, Taga T, Adachi S; Transplantation and Cellular Therapy Committee of Japanese Childhood Cancer Group. Sakaguchi H, et al. Among authors: taga t. BMJ Open. 2023 Apr 17;13(4):e070051. doi: 10.1136/bmjopen-2022-070051. BMJ Open. 2023. PMID: 37068890 Free PMC article.
UBTF-internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemia.
Kaburagi T, Shiba N, Yamato G, Yoshida K, Tabuchi K, Ohki K, Ishikita E, Hara Y, Shiraishi Y, Kawasaki H, Sotomatsu M, Takizawa T, Taki T, Kiyokawa N, Tomizawa D, Horibe K, Miyano S, Taga T, Adachi S, Ogawa S, Hayashi Y. Kaburagi T, et al. Among authors: taga t. Genes Chromosomes Cancer. 2023 Apr;62(4):202-209. doi: 10.1002/gcc.23110. Epub 2022 Dec 7. Genes Chromosomes Cancer. 2023. PMID: 36448876
Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.
Yamato G, Kawai T, Shiba N, Ikeda J, Hara Y, Ohki K, Tsujimoto SI, Kaburagi T, Yoshida K, Shiraishi Y, Miyano S, Kiyokawa N, Tomizawa D, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Taga T, Horibe K, Ogawa S, Hata K, Hayashi Y. Yamato G, et al. Among authors: taga t. Blood Adv. 2022 Jun 14;6(11):3207-3219. doi: 10.1182/bloodadvances.2021005381. Blood Adv. 2022. PMID: 35008106 Free PMC article.
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, Hasegawa D, Terui K, Hama A, Tsujimoto SI, Kiyokawa N, Miyachi H, Deguchi T, Hashii Y, Iijima-Yamashita Y, Taki T, Noguchi Y, Koike K, Koh K, Yuza Y, Moriya Saito A, Horibe K, Taga T, Tanaka S, Adachi S. Tomizawa D, et al. Among authors: taga t. Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6. Leukemia. 2024. PMID: 37926712 No abstract available.
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis.
Yokosuka T, Ito M, Yoshino Y, Hirose A, Nakamura W, Sakurai Y, Hayashi A, Fujita S, Miyagawa N, Keino D, Iwasaki F, Hamanoue S, Yanagimachi M, Goto S, Nagai JI, Ueno H, Takita J, Tanaka Y, Taga T, Goto H. Yokosuka T, et al. Among authors: taga t. Br J Haematol. 2022 Feb;196(3):764-768. doi: 10.1111/bjh.17970. Epub 2021 Nov 23. Br J Haematol. 2022. PMID: 34816427
127 results